Market Cap

Genmab A/S Market Capitalization:

kr.196.04 Billion

DKK as of Jan. 1, 2023

US$28.16 Billion

business Genmab A/S Company Profile

Genmab A/S Main Stock Listing

show_chart OMXC: GMAB

Market Capitalization History of Genmab A/S

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Biotechnology
Company Market Cap (USD)
Novo Nordisk $304.61 B
CSL Limited $93.24 B
Regeneron Pharmaceuticals, Inc. $79.53 B
Marinomed Biotech AG $76.72 B
Vertex Pharmaceuticals Incorporated $74.13 B
Sector: Healthcare
Company Market Cap (USD)
UnitedHealth Group $495.37 B
Johnson & Johnson $461.85 B
Lilly $347.61 B
Novo Nordisk $304.61 B
Pfizer $287.63 B

Yearly evolution of Genmab A/S market cap

Date Market Cap YoY Change
Jan. 1, 2023 kr.196.04 B 34.11%
Jan. 1, 2022 kr.146.18 B -8.94%
Jan. 1, 2021 kr.160.53 B 57.30%
Jan. 1, 2020 kr.102.05 B 64.43%
Jan. 1, 2019 kr.62.06 B -13.73%
Jan. 1, 2018 kr.71.94 B -17.32%
Jan. 1, 2017 kr.87.01 B 54.60%
Jan. 1, 2016 kr.56.28 B 93.99%
Jan. 1, 2015 kr.29.01 B 101.64%
Jan. 1, 2014 kr.14.39 B 124.08%
Jan. 1, 2013 kr.6.42 B 119.48%
Jan. 1, 2012 kr.2.93 B -29.35%
Jan. 1, 2011 kr.4.14 B -35.48%
Jan. 1, 2010 kr.6.42 B -59.86%
Jan. 1, 2009 kr.15.99 B -18.26%
Jan. 1, 2008 kr.19.56 B -17.66%
Jan. 1, 2007 kr.23.75 B 125.16%
Jan. 1, 2006 kr.10.55 B 28.80%
Jan. 1, 2005 kr.8.19 B 81.16%
Jan. 1, 2004 kr.4.52 B 131.54%
Jan. 1, 2003 kr.1.95 B -84.15%
Jan. 1, 2002 kr.12.32 B 0.00%
Jan. 1, 2001 kr.12.32 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

Genmab A/S Categories

Denmark languages Healthcare languages Biotechnology
Denmark Healthcare Denmark Biotechnology

Stocks & Indices

Genmab A/S has the following listings and related stock indices.


Stock: OMXC: GMAB

Stock: FSX: GE9

Stock: OTC: GNMSF

Stock: NASDAQ: GMAB

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.